Compare LX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LX | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.7M | 104.0M |
| IPO Year | 2017 | 2020 |
| Metric | LX | BDTX |
|---|---|---|
| Price | $0.52 | $1.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $2.13 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 843.4K | 688.1K |
| Earning Date | 12-01-2026 | 11-10-2026 |
| Dividend Yield | ★ 71.14% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.35 |
| 52 Week High | $3.88 | $3.97 |
| Indicator | LX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.54 | 35.17 |
| Support Level | N/A | N/A |
| Resistance Level | $0.74 | $1.94 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 3.39 | 6.33 |
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.